Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy
2024-511377-30-00Phase 3Authorised
- Sponsor
- Cytokinetics
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of aficamten in hypertrophic cardiomyopathy (HCM) (4 arms), sponsored by Cytokinetics. Primary endpoints: Change in Valsalva left ventricular outflow tract gradient and Incidence of adverse events and serious adverse events. Planned start Jan 2025; status: authorised.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2024-511377-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511377-30-00.